The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
P53 as a prognostic marker for bladder cancer: a meta-analysis and review
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S., Feng, A.-C., Boyd, S., Skinner, E., Bochner, B., Thangathurai, D., Mikhail, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.666 · Cited by 3,530
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Bast, R. C., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., & Somerfield, M. R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1865 · Cited by 879
Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer
Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S.-C., Nichols, P. W., Skinner, D. G., Jones, P. A., & Cote, R. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311903 · Cited by 783
Meta-analysis of the literature or of individual patient data: is there a difference?
Stewart, L. A., & Parmar, M. K. B. (1993) · The Lancet · doi:10.1016/0140-6736(93)93004-k · Cited by 769
A dynamic role of HAUSP in the p53-Mdm2 pathway
Li, M., Brooks, C. L., Kon, N., & Gu, W. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00157-1 · Cited by 679
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
Cited by
Systematic reviews: CRD's guidance for undertaking reviews in health care
Tacconelli, E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70065-7 · Cited by 3,245
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Altman, D. G., McShane, L. M., Sauerbrei, W., & Taube, S. E. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001216 · Cited by 1,013
Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research
Riley, R. D., Hayden, J. A., Steyerberg, E. W., Moons, K. G. M., Abrams, K., Kyzas, P. A., Malats, N., Briggs, A., Schroter, S., Altman, D. G., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001380 · Cited by 823
Self-citationHernández, S., López-Knowles, E., Lloreta, J., Kogevinas, M., Amorós, A., Tardón, A., Carrato, A., Serra, C., Malats, N., & Real, F. X. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1771 · Cited by 334
Self-citationMallett, S., Timmer, A., Sauerbrei, W., & Altman, D. G. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605462 · Cited by 122
Metadata
- Authors
- Malats, N., Bustos, A., Nascimento, C. M., Fernandez, F., Rivas, M., Puente, D., Kogevinas, M., & Real, F. X.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 6
- Issue
- 9
- Pages
- 678-686
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2140178932
- Cited by
- 317
- References
- 78
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: P53 as a prognostic marker for bladder cancer: a meta-analysis and review. https://app.cochat.ai/papers/10.1016/s1470-2045(05)70315-6
- The paper
- Malats, N., Bustos, A., Nascimento, C. M., Fernandez, F., Rivas, M., Puente, D., Kogevinas, M., & Real, F. X. (2005). P53 as a prognostic marker for bladder cancer: a meta-analysis and review. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(05)70315-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.